Potassium Binders Facilitate Continued RAASi Therapy: Helpful Tips for Clinicians - a podcast by ReachMD

CME credits: 0.25

Valid until: 16-06-2022

Claim your CME credit at https://reachmd.com/programs/cme/potassium-binders-facilitate-continued-raasi-therapy-helpful-tips-for-clinicians/12567/

There is clinical trial-supported evidence for the use of renin-angiotensin-aldosterone system inhibitors (RAASi) in patients with heart failure and reduced ejection fraction. RAASi therapy improves both morbidity and mortality outcomes, and its use is now recommended in published guidelines. However, the achievement of target dosing is often limited or interrupted due to the development of hyperkalemia.

In this case-based activity, Drs. Javed Butler and Ileana Piña discuss the importance of optimizing RAASi therapy in patients with heart failure and how the use of potassium binders can help accomplish this goal. They will also review the risks and benefits of potassium binders, in addition to both short- and long-term use of these agents in the treatment of patients with heart failure.

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD